Search results for "Biological half-life"
showing 4 items of 4 documents
Pharmakologisch-aktive polymere, 18. Körperverteilung und ausscheidungsverhalten von monomerem und polymerem sulfadiazinacrylamid
1979
Sulfadiazinacrylamid was absorbed after oral and intraperitoneal application in rats to a high extent; the absorption from the intraperitoneum was retarded. Glucose treatment delayed the absorption after both application forms. At comparatively high renal and enteral excretion rates the biological half life time of the monomer was estimated to 8 h. A tumouraffinity was not found but there were indications for a preferred storage in the RES. Poly[sulfadiazinacrylamide] was absorbed after intraperitoneal injection to a clear extent, where at the beginning of the treatment under simultaneous glucose load the absorption was delayed. 24 h after injection higher concentrations in metabolic organs…
Studies on the kinetics and renal excretion of low and high molecular weight dextrans in preterm babies, newborns and young infants.
1977
Administration of low and high molecular weight dextrans in the initial phase of shock is no longer controversial. The special conditions in newborns, however, have been insufficiently considered in planning therapy. This investigation aimed at determining the biological half-lives of dextran 40 (Rheomacrodex®) and dextran 60 (Macrodex®) in this age group. The half-life of dextran 40 was found to be 60 min and that of dextran 60 3 h. Preterm babies and newborns excrete up to 25% less dextran 40 and 60 in 24 h than infants and adults. Normal adult values for excretion are only reached towards the end of the first year of life.
Receptor Binding Properties of the New and Specific Thromboxane Receptor Antagonist Bay U 3405
1992
Human platelet membranes were used to characterize the receptor binding properties of the specific thromboxane receptor antagonist 3H-SQ 29548 and the displacement of 3H-SQ 29548 from its binding site by the new thromboxane receptor antagonist Bay u 3405. The specific binding of 3H-SQ 29548 was saturable with an association rate constant of 1 x 10(-11) mol-1 min-1 and a dissociation rate constant of 0.032 min-1. Nonspecific binding of 3H-SQ 29548 was below 10%. When Scatchard plot analysis was performed on equilibrium saturation binding the kD was 69 nmol/l and the Bmax was calculated as 3.9 pmol/mg membrane protein. 3H-SQ 29548 was dose dependently displaced from its binding site by additi…
Clinical pharmacokinetics of atenolol — A review
1982
Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia. No correlation was found between plasma levels of atenolol and blood pressure lowering activity of the drug. After oral administration elimination half life of atenolol is calcula…